Search research articles

Related Concept Videos

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Upstream Processing

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations.

Journal for immunotherapy of cancer·2026

Same author

The promising potential of gene therapy for diabetes mellitus.

Nature reviews. Endocrinology·2024

Same author

Evaluation of a rapid multi-attribute combinatorial high-throughput UV-Vis/DLS/SLS analytical platform for rAAV quantification and characterization.

Molecular therapy. Methods & clinical development·2024

Same author

Erratum: AAV vector production: Troublesome host innate responses in another setting.

Molecular therapy. Methods & clinical development·2023

Same author

Re-administration of AAV vectors by masking with host albumin: A Goldilocks hypothesis.

Molecular therapy : the journal of the American Society of Gene Therapy·2023

Same author

AAV vector production: Troublesome host innate responses in another setting.

Molecular therapy. Methods & clinical development·2023

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Mar 31, 2026

Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production

Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production

Published on: May 3, 2024

Progress and challenges in viral vector manufacturing.

Johannes C M van der Loo¹, J Fraser Wright²

¹The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA and vanderlooj@email.chop.edu.

Human Molecular Genetics

|November 1, 2015

Summary

This summary is machine-generated.

Gene therapy shows promise for treating various diseases, with recent clinical successes driving investment. However, significant manufacturing and regulatory challenges must be overcome for widespread adoption.

More Related Videos

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Published on: May 24, 2012

Related Experiment Videos

Last Updated: Mar 31, 2026

Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production

Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production

Published on: May 3, 2024

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Published on: January 29, 2019

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Published on: May 24, 2012

Area of Science:

Biotechnology and Genetic Medicine
Drug Development and Manufacturing
Regulatory Science

Background:

Gene therapy clinical studies demonstrate significant potential for unmet medical needs.
Recent successes include gene replacement for Hemophilia B, X-SCID, LCA2, and CAR T-cell immunotherapy for hematological malignancies.
The licensure of Glybera highlights progress but also signals manufacturing challenges.

Purpose of the Study:

To provide an overview of current progress in gene therapy.
To discuss the key challenges in gene therapy product manufacturing.
To address the increasing regulatory scrutiny and GMP compliance demands.

Main Methods:

Review of clinical study outcomes and product licensure.
Analysis of viral vector manufacturing capacity requirements.
Examination of regulatory trends and industry partnership demands.

Main Results:

Clinical trial data supports gene therapy's efficacy in various indications.
A substantial increase in viral vector manufacturing capacity is required for commercial supply.
Enhanced regulatory scrutiny and GMP compliance are increasingly demanded at earlier development stages.

Conclusions:

Gene therapy is advancing rapidly, with promising clinical results.
Manufacturing capacity and consistent product quality are critical hurdles for commercialization.
Navigating regulatory requirements and ensuring GMP compliance are essential for industry partnerships.